Gaucher Disease Clinical Trial
Official title:
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Verified date | February 2017 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective:
To study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of
eliglustat.
Secondary Objective:
To assess the tolerability of eliglustat tartrate given as a single dose in subjects with
mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic
function.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion criteria : For subjects with hepatic impairment: - Male or female subjects, between 18 and 79 years of age, inclusive. - Body weight between 50.0 and 125.0 kg, inclusive if male, and between 40.0 and 110.0 kg, inclusive if female, body mass index (BMI) between 18.0 and 37 kg/m^2, inclusive. - Stable chronic liver disease assessed by medical history, physical examination, laboratory values. - For moderate hepatic impairment cohort: Child-Pugh total score ranging from 7 to 9, inclusive. - For mild hepatic impairment cohort: Child-Pugh total score ranging from 5 to 6, inclusive. For matched subjects: - Male or female subjects, between 18 and 79 years of age, inclusive. - Body weight within 15% of the body weight of the subjects with hepatic impairment and BMI between 18.0 and 37 kg/m^2, inclusive. - Matched by cytochrome P450 (CYP) 2D6 predicted phenotype based on genotype. - Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). Exclusion criteria: For subjects with hepatic impairment: - Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. - Hepatocarcinoma. - Acute hepatitis. - Hepatic encephalopathy grade 2, 3, and 4. - Presence or history of drug hypersensitivity, or allergic disease, including active seasonal rhinitis, diagnosed and treated by a physician. - History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day) within 2 years before inclusion. - If female, pregnancy (defined as positive beta-human chorionic gonadotropin [ß -HCG] blood test), breastfeeding. - P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inhibitors and/or inducers. - Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab). - Pre-existing cardiac disease (current congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg, amiodarone, sotalol) anti-arrhythmic medications. - Any subject with CYP2D6 indeterminate or ultra-rapid metabolizer (URM) phenotype. For matched subjects: - Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. - Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. - If female, pregnancy (defined as positive ß-HCG blood test), breastfeeding. - For subjects 50 years of age and younger: any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that medication, whichever the longest, with the exception of hormonal contraception or menopausal hormone replacement therapy, any vaccination within the last 28 days, and any biologics (antibody or its derivatives) given within 4 months before inclusion. - For subjects older than 50 years of age: any significant change in chronic treatment medication within 14 days before inclusion. - P-gp inhibitors and/or inducers, CYP2D6 and/or CYP3A inhibitors and/or inducers. - Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus (anti-HCV) antibodies, anti-HIV1 and anti-HIV2 Ab. - History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day) within 2 years before inclusion. - Pre-existing cardiac disease (current congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, or use of Class IA (eg, quinidine, procainamide) and Class III (eg, amiodarone, sotalol) anti-arrhythmic medications. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
United States | Investigational Site Number 840001 | Knoxville | Tennessee |
United States | Investigational Site Number 840002 | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of PK parameter: Maximum plasma concentration observed (Cmax) | 3 days | ||
Primary | Assessment of PK parameter: Area under the plasma concentration (AUC) | 3 days | ||
Secondary | Assessment of PK parameter: Area under the plasma concentration versus time curve (AUClast) | 3 days | ||
Secondary | Assessment of PK parameter: Apparent total body clearance (CL/F) | 3 days | ||
Secondary | Assessment of PK parameter: Apparent volume of distribution during the terminal phase (Vz/F) | 3 days | ||
Secondary | Assessment of PK parameter: Predicted accumulation ratio (Rac,pred) | 3 days | ||
Secondary | Assessment of PK parameter: Terminal half-life (t1/2z) | 3 days | ||
Secondary | Change from baseline in ECG parameter | Baseline, Up to 10 days | ||
Secondary | Number of adverse events | Up to 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT02536937 -
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
|
Phase 1 | |
Completed |
NCT04430881 -
A National Study in Patients With Unexplained Splenomegaly
|
||
Completed |
NCT01411228 -
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
|
Phase 3 | |
Terminated |
NCT04094181 -
A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
|
||
Completed |
NCT00391625 -
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
|
Phase 1/Phase 2 | |
Completed |
NCT03625882 -
Survey Study for Velaglucerase Alfa (VPRIV) in Japan
|
||
Active, not recruiting |
NCT05526664 -
Omics Gaucher Study: Multiomic Approach
|
||
Completed |
NCT02536755 -
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
|
Phase 3 | |
Recruiting |
NCT01344096 -
Thrombocytopathy in Gaucher Disease Patients
|
N/A | |
Completed |
NCT01881633 -
A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT06116071 -
Biomarkers Related to Bone in Pediatric Gaucher Disease
|
||
Recruiting |
NCT01951989 -
Intra-monocyte Imiglucerase Kinetics in Gaucher Disease
|
Phase 2 | |
Completed |
NCT00258778 -
Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
|
Phase 1 | |
Recruiting |
NCT04388969 -
World Data on Ambroxol for Patients With GD and GBA Related PD
|
||
Recruiting |
NCT05992532 -
GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
|
||
Terminated |
NCT04145037 -
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00302146 -
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
|
||
Active, not recruiting |
NCT02605603 -
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease
|
||
Completed |
NCT02053896 -
A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease
|
Phase 2 |